Kezar Life Sciences (KZR) to Be Acquired by Aurinia Pharmaceuticals (AUPH) Amid Financial Struggles

Font: Financial Modeling Prep  • Mar 31, 2026

Kezar Life Sciences (NASDAQ: KZR) Agrees to Acquisition by Aurinia Pharmaceuticals Amid Ongoing Financial Challenges

Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company focused on developing small-molecule therapies for autoimmune diseases and cancer, has entered into a definitive merger agreement to be acquired by Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).

Under the terms of the agreement announced on March 30, 2026, Kezar shareholders will receive $6.95 in cash per share plus one non-transferable contingent value right (CVR). The CVR provides potential additional payments tied to:

• Ongoing clinical development or disposition of Kezar's lead candidate zetomipzomib (an immunoproteasome inhibitor in development for autoimmune hepatitis, lupus nephritis, and systemic lupus erythematosus);
• Certain proceeds from Kezar's collaboration with Everest Medicines and the prior sale of its Sec61-based discovery program to Enodia Therapeutics;
• 100% of Kezar's closing net cash in excess of $50 million (net of certain post-closing CVR-related expenses).

The transaction will be structured as a tender offer (expected to launch by April 13, 2026), followed by a merger. Closing is subject to conditions including tender of a majority of outstanding shares, Kezar having at least $50 million in closing net cash, and other customary requirements. The deal is anticipated to close in the second quarter of 2026. Kezar's board unanimously approved the transaction, which is supported by key investor Tang Capital Partners (holding ~9% of shares) via a tender and support agreement.

Shareholder Investigations Law firms Ademi LLP and Halper Sadeh LLC have announced investigations into the deal, examining whether Kezar's board breached fiduciary duties, obtained the best possible price for shareholders, conducted a fair sales process free of conflicts of interest, and provided full material disclosures. The firms may seek additional consideration or disclosures on behalf of shareholders.

Financial Performance Kezar continues to face significant financial challenges typical of a pre-commercial biotech. For the full year ended December 31, 2025, the company reported a net loss of approximately $56.0 million (improved from $83.7 million in 2024), with an operating loss of $59.1 million. In its most recent quarterly results (Q4 2025, reported around March 27, 2026), Kezar posted an EPS of -$1.99, missing analyst consensus estimates of around -$1.39. The company has no commercial revenue and maintains a cash runway supported by prior cost-cutting measures, including workforce reductions.

As of the latest available data, Kezar held substantial cash reserves (previously reported near $70–90 million range in prior quarters), a key factor in the deal's net cash condition for the CVR.

Market Reaction and Strategic Context Following the announcement, KZR shares surged approximately 19–21%, trading around $7.45 (a premium to the $6.95 cash offer, reflecting CVR value and deal uncertainty). The acquisition allows Aurinia to expand its autoimmune disease portfolio by adding zetomipzomib, which has shown promising clinical data and recent positive FDA interactions.

The agreement includes provisions that may deter or penalize competing offers, a common feature in such deals. Shareholders should review the definitive proxy/offer documents for full details on risks, CVR mechanics, and their rights.